Carmat

CONGRESS | Meet us at the 45th ISHLT - International Society for Heart and Lung Transplantation Congress 📣 We are delighted to announce our presence at the ISHLT 45th Annual Meeting to be held in Boston, MA USA, from April 27 to 30, 2025 and the presentation session of Pr. Julien Guihaire: “First clinical use of a TAH in a patient with an invasive Mediastinal Tumor”, on April 27, at 4:30 pm (Session 14). 📍Meet the CARMAT team at booth 330, Level 2! We will be delighted to answer your questions about our artificial heart Aeson®. #Carmat #ISHLT #ArtificialHeart #Aeson #Surgery #Transplantation

GOOD NEWS 💙   We are very delighted to announce the FDA conditional approval to initiate the second cohort of the EFS study with Aeson® artificial heart in the United States 🇺🇸✅   This second part of the EFS study represents an important step in the Company’s US market access strategy, the United States being the largest market in the world in the field of implantable cardiac devices.   ➡️ The study’s primary endpoint is patient survival at 6 months post-Aeson® implant, or a successful transplant within this timeframe.   🔜 Initiation of the second cohort of 7 patients expected in H2 2025.   #Carmat #Aeson #ArtificialHeat #Cardiology #FDA

📣 REMINDER | Join us at the 91. DGK-Jahrestagung congress in Mannheim, Germany, from April 23 to 26, 2025. 📅 Don't miss our Symposium ”Physiologic Heart Replacement Therapy (PHRT) for advanced heart failure”, moderated by Prof. Dr. Assad Haneya and Prof. Dr. Nikos Werner, on Wednesday, April 23, 2025, from 5:30 pm to 7:00 pm, Room 7. 📍Meet our German team at Booth 304, Hall 2! We will be delighted to answer your questions about Aeson®. #Carmat #Aeson #91DGK #ArtificialHeart #Cardiology #Heartfailure #DGK Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) Michael Schulz Christian Schmitt Fabian Coy

REPLAY | Presentation of CARMAT’s Q1 2025 achievements and progress 👨💻 Missed our last webinars? The replays are available online. French replay 👉 https://lnkd.in/e2atgPgu English replay 👉https://lnkd.in/eQTWkdgt #CARMAT #Aeson #Webinar

We are pleased to share with you our Q1 2025 achievements and outlook. 📊👇 For more info, read the press release: https://lnkd.in/e3mnkyyW #Carmat #Aeson #ArtificialHeat #Cardiology #Q12025

Un témoignage touchant 💙 Nous sommes heureux de vous partager un article paru dans Le Parisien, qui met en lumière le témoignage saisissant de l’un des patients vivant avec le cœur artificiel Aeson®. Gilbert, 67 ans, explique comment ce coeur artificiel lui a offert une « nouvelle vie », et lui permet de “voir grandir ses petites-enfants”. Merci à Mr. Poudré pour son témoignage, à l’équipe Lilloise d’avoir ouvert les portes de l’Institut Coeur Poumon (Pr. André Vincentelli et Dr. Goéminne), et à Le Parisien pour la mise en perspective de notre technologie qui a déjà sauvé plus de 100 patients souffrant d’insuffisance cardiaque avancée. #Carmat #Aeson #InsuffisanceCardiaque #CoeurArtificiel

At Carmat, we firmly believe that medical innovation only makes sense when it is driven by a united and committed team. ✨ Innovating in healthcare is not just about developing cutting-edge technology. It is about building a new ecosystem, where each stakeholder collaborates and adapts to pave the way forward. 💙 Around our Aeson® artificial heart, an entire ecosystem comes together: surgeons, cardiologists, anesthetists, field experts, proctors, nurses, caregivers, families, and patient support networks. We are proud to bring forward a new therapy, which is not only based on a medical device, but on human synergy. Each Aeson® implant is a testament to what medicine can accomplish when expertise, innovation and trust come together. Thank you to all the healthcare professionals and everyone involved in this exceptional journey! #Carmat #Aeson #CardiacImplantation #WorldHealthDay

We are proud to inform you of a new scientific publication on Aeson® in a peer-reviewed journal! 📰💙 JACC: Heart Failure publishes an initial clinical experience with our Total Artificial Heart in cardiogenic shock patients initially placed on extracorporeal life support. 🏥 The article features the results of a retrospective analysis conducted in seven hospitals across France and Germany between November 2022 and April 2024, on ten patients with refractory cardiogenic shock. 🔎 The analysis shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term. ☑️ Furthermore, Aeson® improves kidney and liver recovery and allows for hospital discharge after a median hospital stay of 42 days, contributing to an improvement in functional capacity and overall health status of the patient while awaiting a heart transplant. For more info, read the article: https://lnkd.in/eHxm7XuE #Carmat #Aeson #JACC #Cardiology #Heartfailure #ECLS Anne-Céline Martin

CARMAT's management is pleased to invite you to an interactive webinar to share the Company's Q1 2025 achievements and progress. 📢📊 Join us on April 9, 2025 at 8:00 pm. 👥 The speakers will be : - Stephane Piat, CEO - Pascale d'Arbonneau, Deputy CEO and CFO - Francesco Arecchi, Director of Global Market Development - Christian Latrémouille, Director of Surgical Affairs Register now! 📌 #CARMAT #Aeson #Webinar

Le management de CARMAT a le plaisir de vous inviter à un webinaire interactif pour partager avec vous les réalisations du premier trimestre 2025 et les perspectives de la société. 📢📊 Rejoignez-nous le 9 avril 2025 à 18h. 👥 Les intervenants seront : - Stephane Piat, Directeur Général - Pascale d'Arbonneau, Directeur Général Adjoint et Directeur Financier - Francesco Arecchi, Directeur Développement du marché mondial - Christian Latrémouille, Directeur des Affaires Chirurgicales Inscrivez vous dès maintenant ! 📌 #CARMAT #Aeson #Webinar